WO2011028860A3 - Composés et compositions pour le traitement du cancer - Google Patents

Composés et compositions pour le traitement du cancer Download PDF

Info

Publication number
WO2011028860A3
WO2011028860A3 PCT/US2010/047615 US2010047615W WO2011028860A3 WO 2011028860 A3 WO2011028860 A3 WO 2011028860A3 US 2010047615 W US2010047615 W US 2010047615W WO 2011028860 A3 WO2011028860 A3 WO 2011028860A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
treating cancer
cancer
diseases
Prior art date
Application number
PCT/US2010/047615
Other languages
English (en)
Other versions
WO2011028860A2 (fr
Inventor
Michael Andrew Foley
Robert Gould
Peter Elliot
Anna Mandinova
Sam Lee
Original Assignee
Canthera Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canthera Therapeutics, Inc. filed Critical Canthera Therapeutics, Inc.
Priority to EP10814469A priority Critical patent/EP2473506A4/fr
Priority to JP2012528029A priority patent/JP2013503888A/ja
Priority to CN2010800418987A priority patent/CN102625805A/zh
Priority to CA2772614A priority patent/CA2772614A1/fr
Priority to IN1878DEN2012 priority patent/IN2012DN01878A/en
Priority to AU2010289493A priority patent/AU2010289493A1/en
Priority to BR112012004701A priority patent/BR112012004701A2/pt
Publication of WO2011028860A2 publication Critical patent/WO2011028860A2/fr
Publication of WO2011028860A3 publication Critical patent/WO2011028860A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des composés et une composition pour le traitement et la prévention contre le cancer. L'invention recouvre également toutes les maladies qui peuvent être traitées par modulation sélective de niveaux d'espèces réactives de l'oxygène dans des cellules malades par rapport à des cellules normales. L'invention concerne également des procédés pour la préparation et l'administration de telles compositions.
PCT/US2010/047615 2009-09-02 2010-09-02 Composés et compositions pour le traitement du cancer WO2011028860A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP10814469A EP2473506A4 (fr) 2009-09-02 2010-09-02 Composés et compositions pour le traitement du cancer
JP2012528029A JP2013503888A (ja) 2009-09-02 2010-09-02 癌を治療するための化合物および組成物
CN2010800418987A CN102625805A (zh) 2009-09-02 2010-09-02 治疗癌症的化合物和组分
CA2772614A CA2772614A1 (fr) 2009-09-02 2010-09-02 Composes et compositions pour le traitement du cancer
IN1878DEN2012 IN2012DN01878A (fr) 2009-09-02 2010-09-02
AU2010289493A AU2010289493A1 (en) 2009-09-02 2010-09-02 Compounds and compositions for treating cancer
BR112012004701A BR112012004701A2 (pt) 2009-09-02 2010-09-02 compostos e composições para tratamento do câncer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27575409P 2009-09-02 2009-09-02
US61/275,754 2009-09-02

Publications (2)

Publication Number Publication Date
WO2011028860A2 WO2011028860A2 (fr) 2011-03-10
WO2011028860A3 true WO2011028860A3 (fr) 2011-07-21

Family

ID=43625764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/047615 WO2011028860A2 (fr) 2009-09-02 2010-09-02 Composés et compositions pour le traitement du cancer

Country Status (9)

Country Link
EP (1) EP2473506A4 (fr)
JP (1) JP2013503888A (fr)
KR (1) KR20120104165A (fr)
CN (1) CN102625805A (fr)
AU (1) AU2010289493A1 (fr)
BR (1) BR112012004701A2 (fr)
CA (1) CA2772614A1 (fr)
IN (1) IN2012DN01878A (fr)
WO (1) WO2011028860A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101629642B1 (ko) 2014-06-25 2016-06-13 서울대학교산학협력단 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물
GB201715008D0 (en) * 2017-09-18 2017-11-01 Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa TRPV2 Antagonists
KR20200081633A (ko) 2018-12-27 2020-07-08 주식회사 티에스디라이프사이언스 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물
CN110002987B (zh) * 2019-03-22 2020-09-15 南通大学 苯基亚烯丙基环己烯酮衍生物及制备方法和用途
CN117229205A (zh) * 2023-09-14 2023-12-15 中国医学科学院基础医学研究所 苯基丙烯酰胺类rhbdd1抑制剂制备方法及制药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112195A1 (fr) * 2007-03-09 2008-09-18 Bioseek, Inc. Méthodes d'identification d'agents et leur utilisation dans la prévention ou la stabilisation de la fibrose
US20080227829A1 (en) * 2007-02-14 2008-09-18 Hammerstone John F Neurogenic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146054A (zh) 2010-02-10 2011-08-10 新昌县来益科技开发有限公司 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227829A1 (en) * 2007-02-14 2008-09-18 Hammerstone John F Neurogenic compounds
WO2008112195A1 (fr) * 2007-03-09 2008-09-18 Bioseek, Inc. Méthodes d'identification d'agents et leur utilisation dans la prévention ou la stabilisation de la fibrose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2473506A4 *

Also Published As

Publication number Publication date
AU2010289493A1 (en) 2012-04-19
KR20120104165A (ko) 2012-09-20
CA2772614A1 (fr) 2011-03-10
EP2473506A2 (fr) 2012-07-11
CN102625805A (zh) 2012-08-01
WO2011028860A2 (fr) 2011-03-10
IN2012DN01878A (fr) 2015-08-21
JP2013503888A (ja) 2013-02-04
BR112012004701A2 (pt) 2018-06-12
EP2473506A4 (fr) 2013-03-06

Similar Documents

Publication Publication Date Title
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2012024530A3 (fr) Conjugués peptide thérapeutique-polymère, particules, compositions et procédés apparentés
WO2011082273A3 (fr) Composés de pyrroloaminopyrimidine substitués
WO2011082267A8 (fr) Composés triazolo-pyrazine substitués
WO2010059004A3 (fr) Composé pouvant empêcher la liaison p53-snail, et agent thérapeutique contre le cancer contenant ce composé en tant que principe actif
WO2008097640A8 (fr) Composés à base de triazole modulant l'activité de hsp90
WO2010078421A8 (fr) Composés de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amines substituées
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2010081032A3 (fr) Compositions stéroïdiennes
WO2010087964A3 (fr) Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés
TW200637488A (en) Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
WO2009095261A3 (fr) Compositions vaccinales
WO2010017541A3 (fr) Compositions et procédés de traitement d'une maladie dégénérative du système nerveux
WO2011119777A3 (fr) Compositions et méthodes de traitement d'une maladie neurodégénérative
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2011028860A3 (fr) Composés et compositions pour le traitement du cancer
WO2011082268A3 (fr) Composés naphthalényl-pyrimidine substitués
WO2012012278A3 (fr) Compositions et procédés pour le traitement de troubles pathologiques associés à gpr35 et/ou au complexe gpr35-herg
WO2008112647A3 (fr) Radical nitroxyde en tant que traitement pour la neurodégénération
WO2011075822A8 (fr) Compositions immunogènes et méthodes correspondantes
WO2013123249A3 (fr) Formulations et méthodes de traitement d'états de l'oreille
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
WO2011100330A3 (fr) Compositions et procédés de prévention ou de traitement d'une infection par un parvovirus humain
WO2008052054A3 (fr) Synergie entre des cellules immunes activées et des thérapies contre le cancer classiques
EA201300540A1 (ru) Способ лечения, облегчения и/или предупреждения колоректального рака

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080041898.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10814469

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2772614

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1878/DELNP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012528029

Country of ref document: JP

Ref document number: 2010814469

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127007113

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010289493

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010289493

Country of ref document: AU

Date of ref document: 20100902

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012004701

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012004701

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120301